DDX3X and prostate cancer: Evidence has shown that DDX3X is overexpressed in glioma, medulloblastoma (MB), meningioma, head and neck squamous cell carcinoma (HNSSC), lung cancer, breast cancer, hepatocellular carcinoma (HCC), gallbladder carcinoma, pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), prostate cancer and sarcoma [27–29, 77, 79, 83, 85, 89, 90, 95, 98, 99, 104, 105].